A study led by the Duke Clinical Research Institute finds that high costs and multiple appeals to insurers are preventing access to PCSK9 inhibitors, a new class of drugs that lowers LDL cholesterol. This file image provided by Amgen Inc. shows the cholesterol-lowering drug Repatha, which is a PCSK9 inhibitor.
A study led by the Duke Clinical Research Institute finds that high costs and multiple appeals to insurers are preventing access to PCSK9 inhibitors, a new class of drugs that lowers LDL cholesterol. This file image provided by Amgen Inc. shows the cholesterol-lowering drug Repatha, which is a PCSK9 inhibitor. Robert Dawson AP
A study led by the Duke Clinical Research Institute finds that high costs and multiple appeals to insurers are preventing access to PCSK9 inhibitors, a new class of drugs that lowers LDL cholesterol. This file image provided by Amgen Inc. shows the cholesterol-lowering drug Repatha, which is a PCSK9 inhibitor. Robert Dawson AP

These cholesterol drugs could be game-changers. But most can’t afford to pay

September 27, 2017 02:44 PM

UPDATED September 27, 2017 02:54 PM

More Videos

  • Durham County jail opens mental health pod

    Kelli Egnaczak, jail mental health supervisor with the Durham County Criminal Justice Resource Center, explains the advantages of consistent staff in the jail's mental health pod on Nov. 9, 2017. The mental health pod opened Oct. 2, 2017.